Dear Sir/Madam, Pursuant to Regulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors of the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Rekvina Laboratories approved standalone unaudited financial results for the quarter and nine months ended 31 December 2025, along with the auditor's limited review report. Revenue from operations for Q3 FY26 stood at Rs. 34.56 lakhs, up from Rs. 19.62 lakhs in Q2 FY26. For 9M FY26, total revenue was Rs. 54.18 lakhs compared to nil in the corresponding prior period, suggesting the trading business only recently commenced operations. The company posted a net loss of Rs. 12.39 lakhs in Q3 (wider than Rs. 3.49 lakhs loss in Q2) and Rs. 19.42 lakhs for 9M FY26 (vs Rs. 9.43 lakhs loss in 9M FY25). Total expenses of Rs. 46.95 lakhs in Q3 and Rs. 73.60 lakhs in 9M continue to outpace revenue. EPS came in at Rs. (0.21) for Q3 and Rs. (0.32) for 9M FY26. The statutory auditor (M. Shah & Co.) issued a clean, unqualified limited review report with no observations or qualifications.
Widening quarterly losses and expenses consistently exceeding revenue are a concern for shareholders, though the recent revenue ramp-up from a nil base shows the pharma trading business is gaining traction. Investors should monitor the company's path to break-even, as the loss per share has roughly doubled year-on-year for both the quarter and 9M period.